机构：[1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, 100730, China.首都医科大学附属北京同仁医院临床科室耳鼻咽喉-头颈外科[2]Beijing Key Laboratory of Nasal Diseases, Beijing Laboratory of Allergic Diseases, Beijing, Institute of Otolaryngology, Beijing, 100005, China.[3]Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, 100730, China.研究所眼科研究所首都医科大学附属北京同仁医院首都医科大学附属同仁医院[4]Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, 100730, China.临床科室变态反应科首都医科大学附属北京同仁医院首都医科大学附属同仁医院
Allergic rhinitis is a highly prevalent chronic inflammatory disorder of the nasal mucosa that poses a significant burden on patients' health and quality of life. Current therapies for allergic rhinitis are unable to reinstate immune homeostasis or are restricted by specific allergens. Potential therapeutic strategies for allergic rhinitis are urgently needed. Mesenchymal stem cells (MSCs) are immune-privileged, have strong immunomodulatory effects, and can be easily isolated from various sources. Thus, MSC-based therapies demonstrate potential for treating inflammatory diseases. Recently, numerous studies have investigated the therapeutic effects of MSCs in animal models of allergic rhinitis. Here, we review the immunomodulatory effects and mechanisms of MSCs on allergic airway inflammation, especially allergic rhinitis, highlight the recent research regarding MSCs in the modulation of immune cells, and discuss the clinical potential of MSC-based therapy for allergic rhinitis.This article is protected by copyright. All rights reserved.
基金：
This work was supported by grants from national key R&D program
of China (2022YFC2504100, 2017YFA0105300), the program for
the Changjiang scholars and innovative research team (IRT13082),
CAMS innovation fund for medical sciences (2019-I2M-
5-
022),
Capital's funds for health improvement and research (2022-1-
1091),
National natural science foundation of China (82171109, 82125007),
and Beijing natural science foundation (Z200014).
第一作者机构：[1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, 100730, China.[2]Beijing Key Laboratory of Nasal Diseases, Beijing Laboratory of Allergic Diseases, Beijing, Institute of Otolaryngology, Beijing, 100005, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, 100730, China.[2]Beijing Key Laboratory of Nasal Diseases, Beijing Laboratory of Allergic Diseases, Beijing, Institute of Otolaryngology, Beijing, 100005, China.[3]Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, 100730, China.[4]Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, 100730, China.[*1]Beijing TongRen Hospital, Capital Medical University, No. 1, DongJiaoMinXiang, DongCheng District, Beijing, China.
推荐引用方式(GB/T 7714)：
Wang Ming,Zhao Ning,Wang Chengshuo,et al.Immunomodulatory properties of mesenchymal stem cells: a potential therapeutic strategy for allergic rhinitis[J].ALLERGY.2023,78(6):1425-1440.doi:10.1111/all.15729.
APA：
Wang Ming,Zhao Ning,Wang Chengshuo,Jin Zi-Bing&Zhang Luo.(2023).Immunomodulatory properties of mesenchymal stem cells: a potential therapeutic strategy for allergic rhinitis.ALLERGY,78,(6)
MLA：
Wang Ming,et al."Immunomodulatory properties of mesenchymal stem cells: a potential therapeutic strategy for allergic rhinitis".ALLERGY 78..6(2023):1425-1440
医学